These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15752926)

  • 1. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?
    Gerstein HC; Rosenstock J
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):137-54. PubMed ID: 15752926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical advances in diabetes].
    Martin S; Scherbaum WA
    Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1461-2. PubMed ID: 16794976
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes and cardiovascular disease: new perspectives.
    Peter R; Rees A
    Curr Opin Lipidol; 2009 Apr; 20(2):145-6. PubMed ID: 19276893
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes.
    Colette C; Monnier L
    Horm Metab Res; 2007 Sep; 39(9):683-6. PubMed ID: 17846977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Earlier treatment may explain diabetes data.
    Abbey DM
    Science; 2009 Feb; 323(5917):1009. PubMed ID: 19229018
    [No Abstract]   [Full Text] [Related]  

  • 7. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of cardiovascular disease in people with dysglycemia.
    Bianchi C; Miccoli R; Penno G; Del Prato S
    Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].
    Seufert J
    Dtsch Med Wochenschr; 2008 May; 133(20):1068-70. PubMed ID: 18461525
    [No Abstract]   [Full Text] [Related]  

  • 10. [How effectively should hyperglycemia be treated in a type 2 diabetes patient?].
    Eriksson J
    Duodecim; 2009; 125(13):1387-94. PubMed ID: 19678494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy and clinical trials: diabetes and cardiovascular risk.
    Peter R
    Curr Opin Lipidol; 2008 Feb; 19(1):101-3. PubMed ID: 18196995
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes and cardiovascular outcomes: finding the silver lining.
    Chen L; Shen YT; Shannon RP
    Minerva Cardioangiol; 2010 Apr; 58(2):253-67. PubMed ID: 20440254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy and clinical trials: glycaemia and prevention of macroangiopathy in type 2 diabetes.
    Bolusani H; Peter R; Rees A
    Curr Opin Lipidol; 2008 Dec; 19(6):629-30. PubMed ID: 18957889
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment and reply on: Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease.
    Gude AB; Christiansen JS
    Expert Opin Pharmacother; 2010 Jun; 11(9):1603-4; author reply 1604. PubMed ID: 20367274
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Nicholls SJ; Rydén L
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S1. PubMed ID: 20489414
    [No Abstract]   [Full Text] [Related]  

  • 19. Basic approach to managing hyperglycemia for the nonendocrinologist.
    Deeg MA
    Am J Cardiol; 2005 Aug; 96(4A):37E-40E. PubMed ID: 16098842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.